Filtered By:
Cancer: Adenocarcinoma
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 766 results found since Jan 2013.
Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma
Matrix Biol. 2022 Nov 11:S0945-053X(22)00134-2. doi: 10.1016/j.matbio.2022.11.002. Online ahead of print.ABSTRACTSeveral collagen subtypes are involved in pancreatic ductal adenocarcinoma (PDAC) desmoplasia, which constrains therapeutic efficacy. We evaluated collagen type VIII alpha 1 chain (COL8A1), whose function in PDAC is currently unknown. We identified COL8A1 expression in 7 examined PDAC cell lines by microarray analysis, western blotting, and RT‒qPCR. Higher COL8A1 expression occurred in 2 gemcitabine-resistant PDAC cell lines; pancreas tissue (n=15) from LSL-KrasG12D/+; Pdx-1-Cre mice with advanced PDAC predisp...
Source: Matrix Biology - November 14, 2022 Category: Molecular Biology Authors: Bin Yan Li Liu Lian Zhao Ulf Hinz Yiqiao Luo Xuefeng An Jury Gladkich Carolina de la Torre Zhenhua Huang Daniel Schrapel Wolfgang Gross Franco Fortunato Michael Sch äfer Matthias M Gaida Ingrid Herr Source Type: research
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer
Cancer Res. 2022 Nov 8:CAN-22-0391. doi: 10.1158/0008-5472.CAN-22-0391. Online ahead of print.ABSTRACTMutational loss of CDKN2A (encoding p16INK4A) tumor suppressor function is a key genetic step that complements activation of KRAS in promoting the development and malignant growth of pancreatic ductal adenocarcinoma (PDAC). However, pharmacologic restoration of p16INK4A function with inhibitors of CDK4 and CDK6 (CDK4/6) has shown limited clinical efficacy in PDAC. Here, we found that concurrent treatment with both a CDK4/6 inhibitor (CDK4/6i) and an ERK MAPK inhibitor (ERKi) synergistically suppresses the growth of PDAC ce...
Source: Cell Research - November 8, 2022 Category: Cytology Authors: Craig M Goodwin Andrew M Waters Jennifer E Klomp Sehrish Javaid Kirsten L Bryant Clint A Stalnecker Kristina Drizyte-Miller Bjoern Papke Runying Yang Amber M Amparo Irem Ozkan-Dagliyan Elisa Baldelli Valerie Calvert Mariaelena Pierobon Jessica A Sorrentin Source Type: research
Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15
CONCLUSION: We demonstrated that rTM had anti-tumor effect and enhancement of cytotoxic effect of GEM for PDAC cells by inhibiting NF-[Formula: see text]B and ERK activation via GPR15 and suggest that rTM is a potential therapeutic option for PDAC.PMID:36191971 | DOI:10.21873/anticanres.15972
Source: Cell Research - October 3, 2022 Category: Cytology Authors: Kenei Furukawa Jianhua Ling Yichen Sun Y U Lu Jie Fu Rui Marukuchi Paul J Chiao Source Type: research
APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway
ConclusionsTaken together, our study implies that A3B promotes cell proliferation, migration, and cell cycle and inhibits cancer cell apoptosis through the p53-mediated signaling pathway. Moreover, A3B could also contribute to chemoresistance in cervical cancer cells. It may be a potential diagnostic biomarker and therapeutic target for chemoresistant cervical cancers.
Source: Frontiers in Oncology - September 29, 2022 Category: Cancer & Oncology Source Type: research
Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery
This study verifies the successful spray drying procedure of LNP-siRNA systems maintaining their integrity and mediating strong gene silencing efficiency on mRNA and protein levels both in vitro and ex vivo. The successful spray drying procedure of LNP-siRNA formulations in 5% lactose solution creates a novel siRNA-based therapy option to target respiratory diseases such as lung cancer, asthma, COPD, cystic fibrosis and viral infections.PMID:36126785 | DOI:10.1016/j.jconrel.2022.09.021
Source: Cancer Control - September 20, 2022 Category: Cancer & Oncology Authors: Christoph M Zimmermann Domizia Baldassi Karen Chan Nathan B P Adams Alina Neumann Diana Leidy Porras-Gonzalez Xin Wei Nikolaus Kneidinger Mircea Gabriel Stoleriu Gerald Burgstaller Dominik Witzigmann Paola Luciani Olivia M Merkel Source Type: research
Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor β1(TGFβ1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells
CONCLUSIONS: Data provided suggest that TGFβ1 modulates the expression of DUSP genes and that upregulation of DUSP26 may be required for TGFβ1-promoted EMT in A549 and PANC1 cells. Further studies should be carried out to elucidate the requirement of individual DUSPs in TGFβ1-associated EMT in tumor cells.PMID:36053282 | DOI:10.1007/s11033-022-07893-1
Source: Cancer Control - September 2, 2022 Category: Cancer & Oncology Authors: Sabire Guler Berrin Zik Abdullah Yalcin Source Type: research
APE1 redox function is required for activation of Yes-associated protein 1 under reflux conditions in Barrett's-associated esophageal adenocarcinomas
CONCLUSION: Our findings established a novel function of APE1 in EAC progression elucidating druggable molecular vulnerabilities via targeting APE1 or YAP1 for the treatment of EAC.PMID:36045416 | DOI:10.1186/s13046-022-02472-5
Source: Clin Med Res - August 31, 2022 Category: Research Authors: Farah Ballout Heng Lu Lei Chen Kannappan Sriramajayam Jianwen Que Zhipeng Meng Timothy C Wang Silvia Giordano Alexander Zaika Oliver McDonald Dunfa Peng Wael El-Rifai Source Type: research
